OmniAb, Inc. (OABI) Financial Analysis & Valuation | Quarter Chart
OmniAb, Inc. (OABI)
OABIPrice: $1.47
Fair Value: 🔒
🔒score
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics... more
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the U... more
Description
Shares
| Market Cap | $167.31M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Matthew W. Foehr |
| IPO Date | 2021-09-30 | CAGR | 0% |
| Employees | 114 | Website | www.omniab.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
OABI chart loading...
Fundamentals
Technicals
| Enterprise Value | $183.29M | P/E Ratio | -2.58 |
| Forward P/E | -4.9 | PEG Ratio | — |
| P/S Ratio | 0.13 | P/B Ratio | 0.01 |
| P/CF Ratio | -0.08 | P/FCF Ratio | -0.06 |
| EPS | $-0.57 | EPS Growth 1Y | -5% |
| EPS Growth 3Y | 507.03% | EPS Growth 5Y | — |
| Revenue Growth 1Y | -29.27% | Gross Margin | 0.73% |
| Operating Margin | -3.7% | Profit Margin | -3.47% |
| ROE | -0.24% | ROA | -0.22% |
| ROCE | -0.24% | Current Ratio | 4.02 |
| Quick Ratio | 4.02 | Cash Ratio | 1.57 |
| Debt/Equity | 0.08 | Interest Coverage | — |
| Altman Z Score | 1.33 | Piotroski Score | 1 |